A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

• Status: Completed
• Trial end date: 2009-05-14
• Target enrollment: 0
• Participant gender: Female

Summary

This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Lorazepam

Criteria

Inclusion Criteria:

• Healthy males

• Non-smokers

• Body weight 50 kg (110 lbs) or higher, and BMI within the range 19-29.9 kg/m2

• Normal ECG.

Exclusion Criteria:

• Any serious medical disorder or condition.

• Any history of an endocrine disorder.

• Any clinically significant laboratory abnormality.

• History of psychiatric illness.

• Any history of suicidal attempts or behavior.

• History or current diagnosis of acute narrow angle glaucoma.

• Left handed